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Abstract 
Hypothyroidism is a disease that affects about one to two percent of the population in the United 
States.  It is a condition of the thyroid gland that involves inadequate production of the thyroid 
hormones, thyroxine (T4) and triiodothyronine (T3).  These changes cause increases in the level 
of serum thyroid stimulating hormone (TSH).  Subclinical hypothyroidism is more prevalent 
than overt hypothyroidism, involving elevated TSH levels with normal T4 levels.  Based on the 
data from the initial visit, it is unclear if the patient had overt hypothyroidism or subclinical 
hypothyroidism.  Controversy exists in the literature as to whether or not subclinical 
hypothyroidism in the asymptomatic patient should be treated with synthetic thyroxine 
replacement.  There is also a lack of consensus regarding best practice for initiating treatment. 
The findings from the literature review support treatment for patients with subclinical 
hypothyroidism who are aged 65 years or under and have a TSH level that is at or above 7.0 
mU/L.  There is also evidence to support treatment for patients off all ages with a TSH that is at 
or above 10 mU/L.  In elderly patients taking thyroid replacement therapy, it is important to 
monitor their TSH levels regularly to avoid overtreatment, as this can lead to adverse effects.   
When considering treatment for subclinical hypothyroidism it is important to carefully evaluate 
the patient’s health status and current medical conditions.  
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The Clinical Benefit of Thyroid Hormone Therapy for Subclinical Hypothyroidism  
Background 
 Hypothyroidism is a disease of the thyroid that is common is the United States.  Affecting 
about one to two percent of the US population (Ross, 2017).  Thyroid hormones, thyroxine (T4) 
and triiodothyronine (T3), are produced by the thyroid gland.  The release of these thyroid 
hormones is regulated by thyroid stimulating hormone (TSH), which is produced by the 
pituitary.  Minor changes in serum free thyroxine cause large, reciprocal changes in TSH levels 
(Ross, 2017).  Hypothyroidism occurs when thyroid hormones are low and the TSH is elevated.  
This is generally determined by drawing a serum TSH and a free T4.  The normal values for 
TSH vary laboratory to laboratory, however the generally accepted normal range of TSH is from 
0.45 mU/L to 4.5 mU/L (Rugge, Bougatsos, & Chou, 2015).  The normal range for free T4 
varies across laboratories also, typical values range from 4.6 to 11.2 mcg/dL (Ross, 2017).  The 
diagnosis of hypothyroidism is based on an elevated level of these lab values.  The rationale for 
providers obtaining a TSH is often based on patient’s presenting symptoms, which can be highly 
variable based on the duration and severity of the deficiency, as well as the age of the patient at 
onset (Ross, 2017).  Some of the common presenting symptoms of hypothyroidism include 
fatigue, mood changes, constipation, dry skin, intolerance to cold, unexplained weight gain and 
muscle aches (Feller et al., 2018; Hennessey & Espaillat, 2015).  Primary hypothyroidism is 
diagnosed when the level of thyroid stimulating hormone is elevated and the free thyroxine level 
is low.  TSH levels fluctuate, therefore a serum TSH is drawn initially.  If elevated, the TSH is 
repeated and a free T4 is also drawn to confirm diagnosis of hypothyroidism (Ross, 2017).  This 
is commonly redrawn in four to six weeks after the initial TSH is collected.  Treatment for 
hypothyroidism includes replacement with synthetic thyroxine, which is administered in an oral 
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pill form called Levothyroxine.  The goals of treatment are to return to normal functioning or 
euthyroid state, which most patients are able to attain with oral levothyroxine.  When treated 
appropriately, the clinical manifestations of the disease are generally reversed (Ross, 2017).  
 Subclinical hypothyroidism is a form of thyroid dysfunction that is diagnosed when there 
is an elevated serum TSH, but the free T4 level is normal.  Patients with this condition are 
generally asymptomatic, although some display vague symptoms of hypothyroidism.  Patients of 
advanced age tend to be less symptomatic or their symptoms are sometimes overlooked due to 
symptoms being associated with the normal aging process (Ross, 2018).  TSH levels increase as 
adults age, therefore subclinical hypothyroidism is more prevalent in the elderly population, 
accounting for an estimated 15% (Hennessey & Espaillat, 2015).  Serum TSH levels can 
fluctuate and elevated levels can be transient (Hennessey & Espaillat, 2015).  When TSH is 
elevated it is important to draw a repeat TSH, along with a free T4 level to confirm diagnosis of 
subclinical hypothyroidism (Ross, 2018).  The literature is inconsistent in its recommendation 
regarding the treatment of subclinical hypothyroidism should be treated with thyroid 
replacement.  Specifically, if the TSH is only mildly elevated or if the patient is asymptomatic 
(Feller et al., 2018).  Untreated subclinical hypothyroidism can lead to overt hypothyroidism in 
some patients and close follow up and monitoring of these patients should be considered (Ross, 
2018).  Research also suggests untreated subclinical hypothyroidism is associated with an 
increased risk of cardiovascular disease such as coronary heart disease, atherosclerosis, heart 
failure, stroke and elevated lipids (Chaker et al., 2015).   There is evidence that subclinical 
hypothyroidism contributes to other medical issues, however the research is conflicting.  Reports 
indicate risk of fractures, fertility problems, nonalcoholic fatty liver disease, and 
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neuropsychiatric symptoms can be impacted by untreated subclinical hypothyroidism (Chaker et 
al., 2015; Ross, 2018).  
 In order to prevent the progression to primary hypothyroidism, most experts agree that if 
the serum TSH value is at or above 10 mU/L it is appropriate to treat with levothyroxine (Ross, 
2018).  In patients who have a serum TSH level between 4.5 mU/L and 10 mU/L there is no 
agreed upon treatment plan (Ross, 2018).  Experts argue the clinical benefit of treatment for 
asymptomatic patients who fall within these ranges may not outweigh the risks.  Discrepancy 
exists among healthcare providers and organizations due to the variation in practice guidelines.  
Inconclusive data has been extracted from previous systematic reviews exhibiting the clinical 
benefit of treatment versus no treatment (Feller et al., 2018).  Overtreatment can occur with 
thyroid replacement therapy as TSH levels fluctuate.  Overtreatment in subclinical 
hypothyroidism occurs when initiation of levothyroxine causes an elevation of free T4 causing 
symptoms of hyperthyroidism including increased risk of fractures or heart arrhythmias. This is 
especially a concern in the elderly population (Hennessey & Espaillat, 2015).  The purpose of 
this case report is to conduct a literature review to determine if there is clinical benefit of thyroid 
hormone therapy for subclinical hypothyroidism. 
Case Report 
 The patient was a 38-year-old female who presented to the clinic for evaluation of fatigue 
and abnormally dry skin.  The patient reported that symptoms started about five months prior to 
the visit.  The patient reported brittle nails, dry skin, and increased intolerance to cold.  The 
patient denied starting any new medications recently.  Her medications included multivitamins 
and probiotics.  She does not have any known allergies.  The patient denied using any new 
perfumes, detergents or lotions. The patient was 12 months post caesarian section, her third 
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caesarian section for pregnancy.   She denied any personal or family history of thyroid or cardiac 
disorders.  She denied any symptoms of shortness of breath, weakness, or palpitations 
 The patient was pleasant and cooperative. She was alert and oriented to person, place and 
time.  She did not appear to be in any acute distress.  She was well groomed and was a good 
historian.  Vital signs were reviewed and were stable.  A physical exam was conducted during 
the clinic visit and was unremarkable, except for visibly dry skin.  The thyroid gland was of 
normal size and consistency, there were no palpable thyroid nodules or abnormalities.  Deep 
tendon reflexes were intact.  Labs were drawn including a complete blood count with 
differential, a complete metabolic panel, and thyroid stimulating hormone.  All labs were 
unremarkable except the TSH, which was elevated at 6.61 mU/L, with a generally accepted 
normal range of 0.45 mU/L to 4.5 mU/L.  The history and physical exam for this patient were 
consistent with hypothyroidism; as indicated by the elevated serum TSH level of 6.61 mU/L.  
There were no previous TSH values available for comparison.  The plan included initiating oral 
thyroid hormone therapy with levothyroxine with a scheduled follow-up appointment in four to 
six weeks to recheck TSH levels and also draw a free thyroxine (T4) level.  At the follow up visit 
in four to six weeks, the plan will be to evaluate the patient’s response to the medication and 
adjust dosage if needed.   
 The patient’s TSH level is elevated and at this point the subsequent labs have not been 
completed; the repeat TSH and free T4 level.  The results of these labs will determine if the 
patient has primary hypothyroidism or subclinical hypothyroidism.  The following report will 
evaluate the literature regarding the clinical benefit of thyroid hormone therapy for subclinical 
hypothyroidism. 
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Literature Review 
 A thorough review of the literature was conducted for this case review.  Searches 
consisted of two databases, CINAHL and PubMed.  The CINAHL database was searched first 
using the phrase “subclinical hypothyroidism” in the first box and “treatment” in the second box. 
Articles were limited to academic journals, geography was set to USA, and the year was limited 
to 2012 through 2019.   This resulted in 56 articles.  PubMed was searched next.  The first search 
conducted utilized the terms “subclinical hypothyroidism treatment.”  This resulted in 2123 
articles.  To limit the number of results, the search was limited to studies from the past 5 years 
and only including human studies. This resulted in 438 articles.  In reviewing the articles, expert 
opinion papers and articles from outside the USA were excluded.  Articles researching 
hypothyroidism in pregnancy were also excluded.  The results of both databases yielded ten 
recent articles relevant to this review.  The literature reviewed included meta-analyses, 
systematic reviews, cohort studies and cross-sectional studies.  
 Untreated subclinical hypothyroidism has been associated as a risk factor for several 
health conditions including increased weight, increased risk of fractures, increased risk of 
mortality and cardiac events.  Garin, Arnold, Lee, Tracy and Cappola (2014) analyzed weight 
and body composition in patients ages 65 years and older to determine if subclinical 
hypothyroidism contributed to weight issues.  They concluded that subclinical hypothyroidism 
was not associated with differences in weight change, lean mass, fat mass, or percent fat when 
compared to patients with euthyroid.  A review by Rugge et al., (2015) also found no evidence to 
support improved body mass index in patients taking thyroid hormone therapy versus patients 
who did not receive thyroid hormone treatment.  Both studies found no improvement in weight 
issues with treatment for subclinical hypothyroidism.  
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 Thyroid dysfunction has also been associated with an increased risk of fractures.  A 
systematic review and meta-analysis was conducted by Wirth et al. (2014) to examine the risk of 
fractures in patients with subclinical thyroid dysfunction.  Findings found no statistically 
significant increased risk for fractures in patients with untreated subclinical hypothyroidism.   
found no statistically significant increased risk for fractures in patients with untreated subclinical 
hypothyroidism.  It was noted that more research is warranted in this area.  Hennessey and 
Espaillat (2015) report an increased risk of fractures in patients aged 60 and older who are taking 
levothyroxine and have TSH levels that are greater than 4 mU/L or less than 0.03 mU/L. 
Indicating the need for close monitoring in elderly patients who are on thyroid hormone therapy.   
 Untreated subclinical hypothyroidism has also been associated with increased risk of 
mortality and cardiac events.  Hyland et al. (2013) evaluated cardiac risk in elderly patients with 
untreated subclinical hypothyroidism.  They found no association between untreated subclinical 
hypothyroidism and the incidence of cardiac conditions, specifically: coronary heart disease, 
heart failure, or cardiovascular death.  Hennessey and Espaillat (2015) also reviewed the risk of 
cardiac events in relation to untreated subclinical hypothyroidism.  They concluded that patients 
with untreated subclinical hypothyroidism, who were ages 65 years and older, were not at an 
increased risk for cardiac mortality or ischemic heart disease. They did find evidence indicating 
that patients who were ages 65 or younger with untreated hypothyroidism were at a greater risk 
for cardiac mortality or ischemic heart disease.  This review reports patients with subclinical 
hypothyroidism aged 70 and younger would benefit from treatment with levothyroxine to 
improve cardiovascular outcomes, they reported no risk reduction for those patients 70 and older 
(Hennessey & Espaillat, 2015).   Along with younger age, the degree of TSH elevation has 
shown increased cardiac risk. TSH levels that are 10 mU/L or higher have been associated with 
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a greater risk of cardiac events and mortality (Hennessey & Espaillat, 2015).  Rhee, Curhan, 
Alexander, Bhan and Brunelli (2013) evaluated over 14,000 people with congestive heart failure 
and compared outcomes for euthyroid patients to those with hypothyroidism and subclinical 
hypothyroidism.  The results of their study indicate greater risk of death in patients who have 
congestive heart failure and subclinical hypothyroidism or hypothyroidism that has not been 
treated.  Rugge et al. (2015) performed an evidence review for the U.S. Preventative Services 
Task Force.  The results indicate there is evidence to support treatment of subclinical 
hypothyroidism to decrease the risk of coronary heart disease.  The risk was lower in those 
treated with thyroid hormone replacement when compared to those whose subclinical 
hypothyroidism was not treated (Rugge et al., 2015).  The evidence supports treatment for 
subclinical hypothyroidism to prevent cardiac events, especially those aged 65-70 or less and 
those with TSH levels at or above 10 mU/L.   
 Rugge et al. (2015) reviewed studies looking at cholesterol levels in patients with 
subclinical hypothyroidism.  They ascertained that there are potentially positive effects on lipid 
levels with thyroid hormone treatment, however, they concluded that the research available is 
limited and the results are inconsistent.  More research is needed in this area to make an 
appropriate recommendation. 
 Subclinical hypothyroidism has also been studied in relation to atrial fibrillation.  A study 
conducted by Baumgartner et al. (2017) reviewed over 30,000 patients to assess the risk of atrial 
fibrillation and thyroid dysfunction.  Their results showed increased risk for atrial fibrillation 
with elevated free T4 levels.  They found that the risk was not increased with elevated TSH 
levels.  In subclinical hypothyroidism, TSH is elevated and free T4 is within normal range.  This 
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study does not correlate untreated subclinical hypothyroidism to the development of atrial 
fibrillation. 
 Chaker et al. (2015) conducted a study with over 47,000 participants focusing on 
subclinical hypothyroidism and the increased risk of stroke.  Their data revealed increased risk of 
fatal stroke in patients with untreated subclinical hypothyroidism that were ages 18 to 49 years of 
age and in the group aged 50 to 64, but not for those over age 65. They also found that higher 
concentrations of TSH, those above 7 mU/L, were associated with increased risk of fatal stroke 
(Chaker et al., 2015).  Based on the evidence, they recommend treatment with thyroid hormone 
replacement in patients who are aged 65 and younger, and also for those with moderately 
elevated TSH of 7 mU/L or higher This evidence supports previous research that recommends 
initiating thyroid hormone therapy for patients with subclinical hypothyroidism who are under 
age 65 and those with moderately elevated TSH levels (Chaker et al., 2015).   
 Hennessey and Espaillat (2015) found a protective factor of levothyroxine in patients 
with chronic kidney disease.  The report indicates levothyroxine “significantly attenuated the 
decline in estimated glomerular filtration rates in 113 participants (mean age 63.2) with Stage 2 
to 4 chronic kidney disease” (Hennessey and Espaillat, 2015, p. 1671).  The use of thyroid 
hormone treatment may help to slow the progression of chronic kidney disease, identifying a  
potential benefit for patients with chronic kidney disease and subclinical hypothyroidism to 
receive treatment with levothyroxine. 
 A meta-analysis and systematic review conducted by Feller et al. reviewed 21 studies, 
including over 2,000 patients with elevated TSH levels looking at the benefit of treatment for 
subclinical hypothyroidism.  Authors cited the importance of the study given the “Relatively 
limited evidence exists from randomized clinical trials (RCTs) to guide therapy for subclinical 
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hypothyroidism.  Systematic reviews have been inconclusive and clinical practice guidelines 
have varied regarding recommendations for managing subclinical hypothyroidism” (Feller et al., 
2018, p. 1350).  Results indicated the use of synthetic T4 replacement with levothyroxine was 
not associated with improvement in overall symptoms.  The treatment group and the placebo 
group exhibited no differences in general quality of life or hypothyroid symptoms (Feller et al., 
2018).  These findings are consistent with a study conducted by Shah (2017), which found that 
the use of levothyroxine for treatment of subclinical hypothyroidism did not provide benefit for 
mood, quality of life, or hypothyroid symptoms.   Almost half of the studies participants returned 
to euthyroid without treatment.  Hennessey and Espaillat (2015) looked at cognitive function and 
mood in elderly adults with subclinical hypothyroidism.  They found no significant difference in 
cognitive function or mood between those treated with levothyroxine and those taking the 
placebo medication.  They also noted that 50% of the patients in the placebo group returned to 
euthyroid by the end of the 12 months period.  These findings are consistent with Rugge et al. 
(2015) that found no correlation with treatment of subclinical hypothyroid and improvements in 
quality of life, cognitive function or blood pressure when compared to patients with no treatment. 
 Treatment guidelines for subclinical hypothyroidism often have variability and depend on 
a variety of clinical considerations.   The recommendations from current clinical guidelines 
value the current research and support the findings from the research conducted by Feller et al. 
(2018).  Feller et al. (2018) found no statistically significant differences between those treated 
with thyroid hormone replacement versus those who were not treated in regard to quality of life 
or signs and symptoms of hypothyroidism.  However, there are other risk factors to consider 
based on the research.  Research indicates there is increased risk for cardiac events in patients 
who are under 65 years of age and those with TSH levels at or above 10 mU/L (Feller et al., 
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2018).  Recent clinical guidelines report, “observational data show a benefit of T4 treatment in 
reducing ischemic heart disease events and overall mortality in younger individuals with 
subclinical hypothyroidism, and we suggest T4 treatment in most patients <65 years of age with 
a TSH ≥7.0 mU/L” (Ross, 2018, what’s new para 1).  Hennessey and Espaillat (2015) 
recommends consideration for treatment for those patients with TSH level at or above 10 mU/L 
to decrease the risk of morbidity.  These recommendations are appropriate based on the body of 
research that was reviewed for this case study.  
 When initiating treatment for subclinical hypothyroidism in the elderly it is 
recommended to start at lower doses and increase slowly to avoid overtreatment and adverse side 
effects.  In all patients, it is important to evaluate their overall health condition and determine if 
treatment is indicated.  Treatment plans should be tailored to the needs of the individual patient 
and followed appropriately with consistent follow up and monitoring.  Research supports the 
benefit from thyroid hormone therapy for subclinical hypothyroidism depending on the age of 
the patient and the concentration of TSH.     
Learning Points 
• When considering treatment for subclinical hypothyroidism; carefully evaluate the 
patient’s health status and current medical conditions to determine appropriateness. 
• Consider treatment in most patients aged 65 years and younger with a TSH ≥7.0 mU/L.  
• Consider treatment for all patients with TSH level at or above 10 mU/L. 
• Treatment of elderly patients often requires lower starting doses with closer lab and 
clinical monitoring to reduce potential adverse effects.  
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